Abstract
The p53 gene suppresses tumor cell growth by inducing cell cycle arrest or apoptosis. Loss of its apoptosis activity has been implicated not only in tumor development but also in chemoresistance. We previously reported that targeting p53 for degradation by the human HPV E6 gene in the ovarian cancer cell line PA1 leads to an increase in the chemoresistant phenotype. Here we investigate the relationship between loss of p53-dependent caspase activation and chemosensitivity. In PA1-neo cells with wild-type p53, the activation of caspases including caspases 9, 8, 7 and 3 and cleavage of PARP were detected following adriamycin or etoposide treatment, whereas no such changes were observed in PA1-E6 cells whose p53 is degraded, suggesting that loss of p53 impairs caspase activation. Importantly, we showed that loss of caspase activation in PA1-E6 cells correlates with increased cell survival. Moreover, PA1 cells overexpressing a dominant negative caspase 9 were found to have decreased caspase-dependent apoptosis, as compared with vector control cells. Furthermore, these dominant negative caspase 9 expressing cells were resistant to chemotherapeutic agent-induced killing. Our results suggest that caspase 9 may be an important target for anticancer drug development. Thus, identifying novel compounds that can activate caspase 9 may be a strategy for overcoming a defect in the p53 apoptosis pathway.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J . 1996 Cell 87: 171
Attardi LD, Lowe SW, Brugarolas J, Jacks T . 1996 EMBO J. 15: 3693–3701
Attardi LD, Reczek EE, Cosmas C, Demicco EG, McCurrach ME, Lowe SW, Jacks T . 2000 Genes Dev. 14: 704–718
Blagosklonny MV . 2000 Leukemia 14: 1502–1508
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B . 1999 J. Clin. Invest. 104: 263–269
Caelle C, Helmberg A, Karin M . 1994 Nature 370: 220–223
Cryns V, Yuan J . 1998 Genes Dev. 12: 1551–1570
Ding HF, Lin YL, McGill G, Juo P, Zhu H, Blenis J, Yuan J, Fisher DE . 2000 J. Biol. Chem. 275: 38905–38911
Ding HF, McGill G, Rowan S, Schmaltz C, Shimamura A, Fisher DE . 1998 J. Biol. Chem. 273: 28378–28383
Fan S, Smith M, Rivet D, Duba D, Zhan Q, Kohn KW, Fornace AJJ, O'Connor PM . 1995 Cancer Res. 55: 1649–1654
Fearnhead HO, Rodriguez J, Govek EE, Guo W, Kobayashi R, Hannon G, Lazebnik YA . 1998 Proc. Natl. Acad. Sci. USA 95: 13664–13669
Gottlieb E, Oren M . 1998 EMBO J. 17: 3587–3596
Green DR . 1998 Cell 94: 695–698
Gu Y, Wu J, Faucheu C, Lalanne JL, Diu A, Livingston DJ, Su MS . 1995 EMBO J. 14: 1923–1931
Haupt Y, Rowan S, Shaulian E, Vousden K, Oren M . 1995 Genes Dev. 9: 2170–2183
Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR . 1993 Proc. Natl. Acad. Sci. USA 90: 3988–3992
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X . 1997 Cell 91: 479–489
Lin Y, Ma W, Benchimol S . 2000 Nat. Genet. 26: 122–127
Lotem J, Sachs L . 1993 Blood 82: 4092–1096
Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T . 1994 Science 266: 807–810
Lowe SW, Ruley HE, Jacks T, Housman DE . 1993a Cell 74: 957–967
Lowe SW, Schmitt EM, Smith SW, Sborne BA, Jacks T . 1993b Nature 362: 847–849
Miyashita T, Harigai M, Hanada M, Reed JC . 1994a Cancer Res. 54: 3131–3135
Miyashita T, Krajewski S, Krajewski M, Wang HG, Lin HK, Liebermann DA, Hoffman B, Reed JC . 1994b Oncogene 9: 1799–1805
Miyashita T, Reed JC . 1995 Cell 27: 293–299
Moroni MC, Hickman ES, Denchi EL, Caprara G, Colli E, Cecconi F, Muller H, Helin K . 2001 Nat. Cell Biol. 3: 552–558
Nakano K, Vousden KH . 2001 Mol. Cell 7: 683–694
Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N . 2000a Science 288: 1053–1058
Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y . 2000b Cell 102: 849–862
Owen-Schaub LB, Zhang W, Cusack JC, Angelo LS, Santee SM, Fujiware T, Roth JA, Deisseroth AB, Zhang WW, Kruzel E, Radinsky R . 1995 Mol. Cell. Biol. 15: 3032–3040
Perkins CL, Fang G, Kim CN, Bhalla KN . 2000 Cancer Res. 60: 1645–1653
Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B . 1997 Nature 389: 300–305
Sabbatini P, Lin J, Levine AJ, White E . 1995 Genes Dev. 9: 2184–2192
Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR . 2000 J. Biol. Chem. 275: 7337–7342
Sherr CJ . 1998 Genes Dev. 12: 2984–2991
Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB . 1993 Cancer Res. 53: 4164–4168
Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW . 1999 Science 284: 156–159
Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, McCombie R, Herman JG, Gerald WL, Lazebnik YA, Cordon-Cardo C, Lowe SW . 2001 Nature 409: 207–211
Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES . 1998 Mol. Cell 1: 949–957
Sun SY, Yue P, Zhou J-Y, Wang Y, Kim HC, Lotan R, Wu GS . 2001 Biochem. Biophys. Res. Commun. 280: 788–797
Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T . 1994 Cell 78: 703–711
Tong X, Howley PM . 1997 Proc. Natl. Acad. Sci. USA 94: 4412–4417
Velculescu VE, El-Deiry WS . 1996 Clin. Chem. 42: 858–868
Wu GS, Burns TF, McDonald ER, Jiang W, Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, Hamilton SR, Spinner NB, Markowitz S, Wu G, El-Deiry WS . 1997 Nature Genet. 17: 141–143
Wu GS, Burns TF, McDonald ER, Meng RD, Kao G, Muschel R, Yen T, El-Deiry WS . 1999 Oncogene 18: 6411–6418
Wu GS, El-Deiry WS . 1996a Nature Med. 2: 255–256
Wu GS, El-Deiry WS . 1996b Clin. Cancer Res. 2: 623–633
Wu GS, Saftig P, Peters C, El-Deiry WS . 1998 Oncogene 16: 2177–2183
Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B . 2001 Mol. Cell 7: 673–682
Acknowledgements
We thank Dr Bert Vogelstein (Johns Hopkins University, Baltimore, MD, USA) for HCT116 cells and Dr Emad Alnemri (Thomas Jefferson University, Philadelphia, PA, USA) for the pcDNA3-DN-caspase 9 expressing vector. We also thank Dr Stuart Ratner for his critical reading of the manuscript. This work was supported by a start-up fund from the Karmanos Cancer Institute.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wu, G., Ding, Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene 21, 1–8 (2002). https://doi.org/10.1038/sj.onc.1205020
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205020
Keywords
This article is cited by
-
Endoplasmic reticulum stress-related gene model predicts prognosis and guides therapies in lung adenocarcinoma
BMC Bioinformatics (2023)
-
Combined dandelion extract and all-trans retinoic acid induces cytotoxicity in human breast cancer cells
Scientific Reports (2023)
-
Targeted Inhibition of Hsp90 in Combination with Metformin Modulates Programmed Cell Death Pathways in A549 Lung Cancer Cells
Applied Biochemistry and Biotechnology (2023)
-
Relationship Between CASP9 and CASP10 Gene Polymorphisms and Cancer Susceptibility: Evidence from an Updated Meta-analysis
Applied Biochemistry and Biotechnology (2021)
-
Chinese medicine formula “Shenqi San” extract inhibits proliferation of human lung adenocarcinoma A549 cells via inducing apoptosis
Current Medical Science (2017)